Dr Richard Glenn Coleman, MD | |
7103 116th Ave, Fennville, MI 49408-9730 | |
(269) 227-3459 | |
Not Available |
Full Name | Dr Richard Glenn Coleman |
---|---|
Gender | Male |
Speciality | General Practice |
Location | 7103 116th Ave, Fennville, Michigan |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679998017 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208D00000X | General Practice | 4301032173 (Michigan) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Richard Glenn Coleman, MD 7103 116th Ave, Fennville, MI 49408-9730 Ph: (269) 227-3459 | Dr Richard Glenn Coleman, MD 7103 116th Ave, Fennville, MI 49408-9730 Ph: (269) 227-3459 |
News Archive
A strategic alliance announced today between TGen Drug Development (TD2) and Horizon Discovery Limited will significant advance personalized medicine.
At least two common gene variants are linked to "clinically meaningful" differences in pain scores in children after major surgery, reports a study in the January issue of Anesthesia & Analgesia, official journal of the International Anesthesia Research Society (IARS).
Since 2007, clinical trials using gene therapy have resulted in often-dramatic sight restoration for dozens of children and adults who were otherwise doomed to blindness. Now, researchers from the Perelman School of Medicine at the University of Pennsylvania and The Children's Hospital of Philadelphia, have found evidence that this sight restoration leads to strengthening of visual pathways in the brain, published this week in Science Translational Medicine.
Magellan Health Services, Inc. today reported net revenue of $728.1 million, net income of $25.5 million or $0.73 per diluted common share, and segment profit, representing income from continuing operations before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, special charges or benefits, and income taxes, of $61.4 million for the quarter ended March 31, 2010.
› Verified 8 days ago